On-Demand CGT Formulation Webinars

  1. Key Considerations For Shortening Your CAR-T Manufacturing Process 3/31/2025

    Explore the development of an automated CAR-T cell therapy process using an innovative platform as well as learn strategies to optimize vein-to-vein time and enhance CAR-T cell shelf life for better patient outcomes.

  2. An Automated System For Rapid Manufacturing Of Engineered T-Cells 3/31/2025

    Discover an innovative TCT-LS process for CAR-T cell therapy that targets blood cancers, solid tumors, and infectious diseases, as well as learn about its unique features, limitations, and how it enhances strategies.

  3. Flow Cytometric Assays For CAR-T Cell Manufacturing 3/31/2025

    Join Dr. Stephen Wilmes, PhD, as he explores the critical role of flow cytometry in analyzing CAR-T cell products to focus on identity, purity, potency, and new technologies enhancing assay sensitivity.

  4. The Next Frontier In mRNA: Modular Manufacturing For Scalable RNA-LNP Therapies 1/29/2025

    Explore constructing a modular RNA-LNP GMP facility using Cytiva's FlexFactory™ process train in a KUBio™ environment to scale RNA-LNP therapies.

  5. Analytical Solutions To Help Accelerate Bioprocessing Success 11/1/2024

    Unlock the power of data-driven bioprocessing. Discover how advanced analytics can optimize your cell culture process, improve performance, and accelerate success.

  6. How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing 5/23/2024

    Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.

  7. An Early Formulation Screening Service 5/23/2024

    Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

  8. Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles 4/25/2024

    The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?

  9. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

    mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

  10. mRNA LNP Scale Up For GMP Vaccine Production 4/14/2022

    Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.